MAIMON RESEARCH LLC: A NEW START RESEARCH AGENDA IN HEALTH TECHNOLOGY ASSESSMENT

SUPPORTING THE CREDIBILITY, EVALUATION AND REPLICATION OF VALUE CLAIMS FOR PHARMACEUTICAL PRODUCTS AND DEVICES

Maimon Research LLC is a long established boutique consulting company specializing in health technology assessment, together with advising and implementing market access strategies to support pharmaceutical products and devices over their life cycle.

The focus of Maimon Research is on developing claims for pharmaceutical products and devices that meet the standards of normal science: value claims that are credible, evaluable, and replicable.

This sets Maimon Research apart from other health technology assessment consultants who support the mainstream in health technology assessment focused on the invention of imaginary value claims. . Unlike competitors, Maimon Research rejects the pseudoscience of assumption driven modeled value claims, offering instead a unique and methodologically acceptable approach to credible claims, their assessment, and replication in target patient populations.

Maimon research puts to one side the approximate information meme promoted by academic and other leaders in health technology assessment; a false belief system that has lasted for over 30 years.

Instead, Maimon Research offers a new start in technology assessment with value claims that support the standards of normal science and the axioms of fundamental evidence. Modeling is rejected as an absurd waste of time and effort to produce any number of competing modeled claims in favor of single attribute value claims that meet required ratio or interval measurement properties. This means that the recently released CHEERS 22 guidance for economic evaluations should be rejected out of hand.

The dominant assumption driven technology assessment meme is an intellectual and analytical dead end. It has to be abandoned in favor of value assessment frameworks that make sense for formulary committees.

The purpose of this website is to introduce prospective clients to the case made in a number of commentaries authored by Dr Paul C Langley, Director, Maimon Research for the standards required to make product claims that meet those of normal science. Links are provided to publications and commentaries which have evaluated approximate information claims.

Maimon Research Services:

•developing value claims that are credible, evaluable, and replicable through supporting health technology assessments that meet standards of normal science

•supporting payers in developing standards for formulary evaluation that are meaningful and meet the standards of normal science

•developing formulary submission protocols for comparative claims validation

•ensuring claims reflect the needs of patients through outcomes instruments that are patient centric

•supporting the rejection of invalid claims, such as lifetime cost per QALY models, by formulary committees

•seminars and training programs to support the new start research agenda